Anixa Common Stock Total Equity from 2010 to 2024

ANIX Stock  USD 3.20  0.14  4.58%   
Anixa Biosciences Common Stock Total Equity yearly trend continues to be fairly stable with very little volatility. Common Stock Total Equity will likely drop to about 264.2 K in 2024. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
1999-07-31
Previous Quarter
310 K
Current Value
310 K
Quarterly Volatility
16.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Anixa Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anixa Biosciences' main balance sheet or income statement drivers, such as Interest Expense of 216.9 K, Selling General Administrative of 4.2 M or Total Revenue of 229.4 K, as well as many indicators such as Price To Sales Ratio of 861, Dividend Yield of 0.0 or PTB Ratio of 4.39. Anixa financial statements analysis is a perfect complement when working with Anixa Biosciences Valuation or Volatility modules.
  
Check out the analysis of Anixa Biosciences Correlation against competitors.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Latest Anixa Biosciences' Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Anixa Biosciences over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Anixa Biosciences' Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anixa Biosciences' overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Anixa Common Stock Total Equity Regression Statistics

Arithmetic Mean612,298
Geometric Mean347,611
Coefficient Of Variation123.28
Mean Deviation573,678
Median278,100
Standard Deviation754,820
Sample Variance569.8B
Range2.1M
R-Value(0.58)
Mean Square Error409.7B
R-Squared0.33
Significance0.02
Slope(97,282)
Total Sum of Squares8T

Anixa Common Stock Total Equity History

2024264.2 K
2023278.1 K
2020309 K
2019242.5 K
2018203.3 K
2017189.1 K
2016166 K

About Anixa Biosciences Financial Statements

Anixa Biosciences investors use historical fundamental indicators, such as Anixa Biosciences' Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Anixa Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Common Stock Total Equity278.1 K264.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.